Sac-TMT Combo Meets PFS End Point in PD-L1–Negative NSCLC Trial
- The Independent Data Monitoring Committee found that the Phase III OptiTROP-Lung06 trial of sacituzumab tirumotecan combined with pembrolizumab met its primary endpoint of improving progression-free survival in PD-L1-negative non-squamous non-small cell lung cancer patients.
- The OptiTROP-Lung06 trial showed a statistically significant improvement in progression-free survival over pembrolizumab with chemotherapy and indicated a positive trend in overall survival.
- The safety profile of sacituzumab tirumotecan plus pembrolizumab was consistent with previous studies with no new safety concerns identified.
- These positive Phase III results support expanding sacituzumab tirumotecan plus immunotherapy for first-line treatment in PD-L1-negative non-squamous non-small cell lung cancer, benefiting a broader patient population.
35 Articles
35 Articles
The Logan Banner
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
As a head-to-head Phase III trial comparing sac-TMT plus pembrolizumab with the first-line standard of care (immunotherapy plus chemotherapy), OptiTROP-Lung06 demonstrated the superiority of replacing conventional pemetrexed/platinum chemotherapy with sac-TMT, with significantly prolonged PFS and a positive OS trend compared…
Kelun-Biotech's Phase III lung cancer trial meets endpoint
CHENGDU, China, July 15, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced today that the Independent Data Monitoring Committee (IDMC) concluded that the Phase III clinical study (OptiTROP-Lung06) of its trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®), in combination w…
Coverage Details
Bias Distribution
- 72% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
